In vivo administration of interleukin-2 protects susceptible mice from Theiler's virus persistence.
AUTOR(ES)
Larsson-Sciard, E L
RESUMO
In vivo administration of interleukin-2 (IL-2)-secreting tumor cells results in complete protection against persistent infection by Theiler's murine encephalomyelitis virus (TMEV) in susceptible DBA/2 mice. The IL-2-mediated protection was found to depend on the inoculum size as well as the timing of IL-2 administration. IL-2-treated and TMEV-infected mice displayed a three- to fourfold relative increase in virus-specific cytotoxic T-lymphocyte (CTL) precursors. Thus, we postulate that the persistence of TMEV infection in susceptible mice reflects limited numbers of relevant CTL precursors and their time course of induction and activation.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=191120Documentos Relacionados
- Role of sialyloligosaccharide binding in Theiler's virus persistence.
- Prophylactic administration of interleukin-2 protects mice from lethal challenge with gram-negative bacteria.
- H-2Db−/− Mice Are Susceptible to Persistent Infection by Theiler's Virus
- An early, abundant cytotoxic T-lymphocyte response against Theiler's virus is critical for preventing viral persistence.
- Administration in vivo of recombinant interleukin 2 protects mice against septic death.
